Transgene Biotek Limited (BOM:526139)

Market Cap	235.64M -25.6%
Revenue (ttm)	3.61M +38.5%
Net Income	-16.53M
EPS	-0.22
Shares Out	75.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,457
Open	3.170
Previous Close	3.130
Day's Range	3.020 - 3.220
52-Week Range	1.830 - 5.260
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Transgene Biotek

Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. T...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Country: India
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 526139

Financial Performance

In fiscal year 2026, Transgene Biotek's revenue was 3.61 million, an increase of 38.51% compared to the previous year's 2.61 million. Losses were -16.53 million, 144.5% more than in 2025.